The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting continued private equity appetite for healthcare technology, Altaris has agreed to acquire Simulations Plus. According to reports, the deal is valued at approximately $375 million, with Altaris seeking to take the company private. The acquisition aims to integrate the firm's modeling and simulation software for pharmaceutical discovery into Altaris's broader portfolio of healthcare and technology assets.
This transaction occurs as the biosimulation software sector experiences significant growth, with peers such as Certara (CERT) expanding market share through AI-driven technologies. Per market data, Simulations Plus previously maintained a market capitalization near $850 million during peak cycles, suggesting the current acquisition price reflects a strategic valuation of its specialized operations. Compared to historical sector deals, the valuation multiples indicate optimism regarding the future of drug development software.
Sign in to access this content
Sign InInvestors should monitor the share price of Simulations Plus (SLP) as it converges toward the offer price following the announcement. Looking at the economic calendar, market participants are awaiting the U.S. Producer Price Index (PPI) data on June 11, 2026, which may influence financing costs for future M&A activity. Analysts will also be watching for further disclosures regarding the closing timeline and necessary regulatory approvals.